Oculis Reports Results of OCS-01 in P-II (DX-211) Study for the Treatment of Diabetic Macular Edema
Shots:
- The P-II (DX-211) study evaluates the safety & efficacy of topical OCS-01 in patients with DME. Oculis is currently evaluating OSC-01 in an ongoing P-III (DIAMOND) trial
- The results from the study demonstrated that OCS-01 was superior to the vehicle in the primary efficacy analysis of BCVA change from baseline with a group difference of +1.58 ETDRS letters at the pre-specified significance level of 0.15 indicating reduced central macular thickness & improved visual acuity
- The mean CMT showed a great decline from baseline in the OSC-01 group vs. vehicle at all post-baseline time points (≤12wks.) & reversed towards baseline with treatment stopped at 12wks. indicating an effect of ONS-01 on retinal edema
Ref: GlobeNewswire | Image: Oculis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
